Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ»ç¼±Ä¡·á¿¡¼­ Åõ°ú¼±·®À» ÀÌ¿ëÇÑ Ã¼³»¼±·® °ËÁõÇÁ·Î±×·¥ °³¹ß

Development of Dose Verification Method for In vivo Dosimetry in External Radiotherapy

Progress in Medical Physics
2014³â 25±Ç 1È£ p.23 ~ p.30
ȲÀÇÁß ( Hwang Ui-Jung ) - ±¹¸³Áß¾ÓÀÇ·á¿ø ¹æ»ç¼±Á¾¾çÇаú

¹éżº ( Baek Tae-Seong ) - °í·Á´ëÇб³ ¹ÙÀÌ¿ÀÀ¶ÇÕ°øÇаú
À±¸í±Ù ( Yoon Myong-Geun ) - °í·Á´ëÇб³ ¹ÙÀÌ¿ÀÀ¶ÇÕ°øÇаú

Abstract

¹æ»ç¼±Ä¡·á¿¡¼­´Â ȯÀÚ Ã¼³»¿¡ Àü´ÞµÈ ¼±·®ÀÌ ¿ø·¡ ÀǵµÇÑ µ¥·Î ºÐÆ÷µÇ´Â Áö È®ÀÎÇϱâ À§ÇÏ¿© ±ÕÁúÇÑ ÆÒÅÒÀ» ÀÌ¿ëÇÑ Á¤
µµ °ü¸®¸¦ Ä¡·á Àü¿¡ ÁÖ·Î ½ÃÇàÇϰí ÀÖ´Ù. ÇÏÁö¸¸ ±ÕÁúÇÑ ÆÒÅÒÀ» ÀÌ¿ëÇÑ Á¤µµ °ü¸®´Â Ç¥¸éÀÌ ºÒ±ÔÄ¢ÀûÀÌ°í ºÒ±ÕÁúÇÑ ÀÎ
ü¿¡ ´ëÇÑ ¼±·®ºÐÆ÷¸¦ ¿ÏÀüÈ÷ º¸ÁõÇØ ÁÖÁö´Â ¸øÇϰí ÀÖ´Ù. º» ¿¬±¸¿¡¼­´Â ȯÀÚ¸¦ Åõ°úÇÏ´Â ¼±·®ÀÇ ºÐÆ÷¸¦ ÃøÁ¤ÇÏ¿© ¿ªÀ¸
·Î ȯÀÚü³» ¼±·® ºÐÆ÷¸¦ °è»êÇÏ´Â Åõ°ú¼±·® ±â¹Ý ü³»¼±·® °ËÁõÇÁ·Î±×·¥À» °³¹ßÇÏ¿´´Ù. Åõ°ú¼±·®Àº ÁÖ¹æ»ç¼±°ú »ê¶õ¹æ
»ç¼±À¸·Î ÀÌ·ç¾îÁ® Àִµ¥, º» ¿¬±¸¿¡¼­´Â ÀüÀÚÆ÷Å»¿µ»óÀåÄ¡·Î ÃøÁ¤ÇÑ ¼±·®ºÐÆ÷·ÎºÎÅÍ ÁÖ¹æ»ç¼±¸¸À» ÀÌ¿ëÇÑ °£´ÜÇÑ ½Ä
À¸·Î ȯÀÚü³»¼±·®ºÐÆ÷¸¦ °è»êÇÏ´Â ÇÁ·Î±×·¥°ú °¨¸¶°ª ºÐÆ÷¸¦ Æò°¡ÇÏ¿© µÎ ¼±·®ºÐÆ÷¸¦ ¼­·Î ºñ±³ÇÒ ¼ö ÀÖ´Â ÇÁ·Î±×·¥À»
°³¹ßÇÏ¿´´Ù. °³¹ßµÈ ÇÁ·Î±×·¥À» ÀÌ¿ëÇÏ¿© °è»êÇÑ ÆÒÅÒÀÇ µîÁß½ÉÁ¡À» Áö³ª´Â °ü»ó¸éÀÇ Ã¼³»¼±·® ºÐÆ÷´Â Ä¡·á°èȹ½Ã½ºÅÛ
¿¡¼­ Á¦°øÇÏ´Â µ¿ÀÏ Æò¸éÀÇ ¼±·®ºÐÆ÷¿ÍÀÇ ºñ±³°á°ú ±ÕÁúÆÒÅÒ¿¡¼­ Æò±Õ 95%, ºñ±ÕÁúÆÒÅÒ¿¡¼­ 81.8%ÀÇ °¨¸¶Åë°úÀ²À» º¸
¿´´Ù.
The purpose of this study is to evaluate the developed dose verification program for in vivo dosimetry based on transit dose in radiotherapy. Five intensity modulated radiotherapy (IMRT) plans of lung cancer patients were used in the irradiation of a homogeneous solid water phantom and anthropomorphic phantom. Transit dose distribution was measured using electronic portal imaging device (EPID) and used for the calculation of in vivo dose in patient. The average passing rate compared with treatment planning system based on a gamma index with a 3% dose and a 3 mm distance-to-dose agreement tolerance limit was 95% for the in vivo dose with the homogeneous phantom, but was reduced to 81.8% for the in vivo dose with the anthropomorphic phantom. This feasibility study suggested that transit dose-based in vivo dosimetry can provide information about the actual dose delivery to patients in the treatment room.

Ű¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í
(Target field)
¿¬±¸´ë»ó
(Population)
¿¬±¸Âü¿©
(Sample size)
´ë»ó¼ºº°
(Gender)
Áúº´Æ¯¼º
(Condition Category)
¿¬±¸È¯°æ
(Setting)
¿¬±¸¼³°è
(Study Design)
¿¬±¸±â°£
(Period)
ÁßÀç¹æ¹ý
(Intervention Type)
ÁßÀç¸íĪ
(Intervention Name)
Ű¿öµå
(Keyword)
À¯È¿¼º°á°ú
(Recomendation)
¿¬±¸ºñÁö¿ø
(Fund Source)
±Ù°Å¼öÁØÆò°¡
(Evidence Hierarchy)
ÃâÆÇ³âµµ
(Year)
Âü¿©ÀúÀÚ¼ö
(Authors)
´ëÇ¥ÀúÀÚ
(1st Authors)
Doi
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå